CNS Pharmaceuticals, Inc. (CNSP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CNSP SEC filings page.
This page shows CNS Pharmaceuticals, Inc. (CNSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External funding supports an expense-led business while research spending stays near $10M and operating losses remain around $15M annually.
In FY2025, operating cash flow was-$13.8M , nearly matching free cash flow of-$13.8M , so the reported loss was not mainly created by heavy capital spending. The simultaneous$14.6M financing inflow indicates that external funding, rather than operations, supplied the cash offset.
Research and development remained near
Balance-sheet flexibility narrowed: debt-to-equity rose from 0.4x in FY2024 to 0.9x in FY2025, while the current ratio fell from 3.4x to 2.0x. The reported liquidity comparison was 6.3 months of FY2025 operating outflow, adding context to the weaker short-term cushion.
Financial Health Signals
CNS Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CNS Pharmaceuticals, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass.
CNS Pharmaceuticals, Inc. reported a net loss of $16K while operations used $13.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
CNS Pharmaceuticals, Inc. reported an operating loss of $16.0M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CNS Pharmaceuticals, Inc.'s EBITDA was -$2.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.7% from the same quarter a year earlier. Against the prior quarter it is up 45.9%.
CNS Pharmaceuticals, Inc. reported -$2.6M in net income in Q2 2026. This represents a decrease of 9.0% from the same quarter a year earlier. Against the prior quarter it is up 47.6%.
Not reported for Q2 2026.
Cash & Balance Sheet
CNS Pharmaceuticals, Inc. recorded an outflow of $3.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 33.7% from the same quarter a year earlier. Against the prior quarter it is up 23.9%.
CNS Pharmaceuticals, Inc. held $20.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
CNS Pharmaceuticals, Inc.'s ROE was -14.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6939.3 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
CNS Pharmaceuticals, Inc. invested $1.2M in research and development in Q2 2026. This represents an increase of 2.9% from the same quarter a year earlier. Against the prior quarter it is down 66.1%.
CNS Pharmaceuticals, Inc. invested $4K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 38.2%.
Not reported for Q2 2026.
CNSP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.2M+2.9% | $3.5M+9.3% | N/A | $2.2M-48.2% | $1.2M+4.5% | $3.2M+33.4% | N/A | $4.2M+24.5% |
| SG&A Expenses | $1.5M+20.7% | $1.4M+30.8% | N/A | $1.1M-23.7% | $1.2M-12.0% | $1.1M-1.8% | N/A | $1.4M+23.2% |
| Operating Income | -$2.7M-12.1% | -$5.0M-14.7% | N/A | -$3.3M+42.2% | -$2.4M+4.7% | -$4.3M-22.4% | N/A | -$5.6M-24.2% |
| EBITDA | -$2.7M-11.7% | -$5.0M-14.7% | N/A | -$3.3M+42.2% | -$2.4M+4.7% | -$4.3M-22.4% | N/A | -$5.6M-24.2% |
| Interest Expense | $4K0.0% | $6K-1.6% | N/A | $2K-6.3% | $4K-10.4% | $6K-6.3% | N/A | $2K+22.9% |
| Net Income | -$2.6M-9.0% | -$4.9M-14.8% | N/A | -$3.2M+42.6% | -$2.4M+6.2% | -$4.3M-21.3% | N/A | -$5.6M-23.9% |
| EPS (Basic) | -$0.38+94.1% | -$7.30+61.4% | -$10.15+72.8% | -$5.76-3659.8% | -$6.42+99.8% | -$18.93-1755.0% | -$37.33+99.7% | -$0.15+99.7% |
| EPS (Diluted) | -$0.38 | -$7.30 | -$10.15 | -$5.76 | -$6.42 | -$18.93 | -$37.33 | -$153.20 |
| Diluted Shares (Avg) | 7M | 676,172 | N/A | 558,868 | 370,127 | 227,220 | N/A | 36,593 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
CNSP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.9M+51.2% | $4.7M-66.2% | $8.6M-0.9% | $11.9M+60.2% | $14.5M+487.5% | $13.7M+727.8% | $8.7M+411.6% | $7.4M+218.3% |
| Current Assets | $21.9M+55.1% | $4.1M-70.3% | $8.1M-6.4% | $11.4M+54.2% | $14.1M+559.0% | $13.7M+756.9% | $8.7M+444.2% | $7.4M+258.3% |
| Cash & Equivalents | $20.0M+64.8% | $3.0M-77.4% | $7.2M+11.4% | $9.9M+41.5% | $12.1M+713.2% | $13.0M+1500.5% | $6.5M+1077.5% | $7.0M+666.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.7M+170.3% | $4.6M+64.9% | $4.1M+62.4% | $2.0M-51.7% | $1.4M-79.6% | $2.8M-54.4% | $2.5M-58.8% | $4.1M-0.3% |
| Current Liabilities | $3.7M+170.3% | $4.6M+64.9% | $4.1M+62.4% | $2.0M-51.7% | $1.4M-79.6% | $2.8M-54.4% | $2.5M-58.8% | $4.1M-0.3% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | $18.2M+38.7% | $71K-99.4% | $4.5M-26.8% | $9.9M+195.6% | $13.1M+405.7% | $11.0M+347.6% | $6.2M+239.4% | $3.4M+292.6% |
| Retained Earnings | -$107.8M-18.3% | -$105.2M-18.6% | -$100.3M-18.8% | -$94.3M-16.1% | -$91.1M-20.4% | -$88.7M-21.4% | -$84.4M-21.4% | -$81.2M-26.6% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CNSP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.5M+33.8% | -$4.6M-43.4% | -$3.1M+44.2% | -$2.2M+68.0% | -$5.3M-223.8% | -$3.2M-1.6% | -$5.5M-115.7% | -$6.8M-101.4% |
| Depreciation & Amortization | $11K+1136.9% | $2K+69.8% | $1K+3.6% | $898+19.6% | $900+19.7% | $1K+34.5% | $985+3.4% | $751-16.5% |
| Stock-Based Compensation | $2K-90.9% | $3K-95.9% | N/A | N/A | $22K | $62K-69.3% | N/A | N/A |
| Capital Expenditures | $4K | $6K | N/A | N/A | $0 | $0 | $4K+94.2% | N/A |
| Free Cash Flow | -$3.5M+33.7% | -$4.7M-43.6% | N/A | N/A | -$5.3M | -$3.2M | -$5.5M-115.7% | N/A |
| Investing Cash Flow | -$4K | -$6K | N/A | N/A | $0 | $0 | -$4K-94.2% | N/A |
| Financing Cash Flow | $20.6M+364.9% | $405K-95.9% | $407K-91.8% | -$92K-100.7% | $4.4M+90.2% | $9.8M+184.2% | $5.0M+127.9% | $12.3M+146826.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CNSP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -14.2%+3.9pp | -6953.5%-6914.3pp | N/A | -32.5%+134.7pp | -18.1% | -39.2% | N/A | -167.2% |
| Return on Assets | -11.8%+4.6pp | -106.1%-74.8pp | N/A | -27.1%+48.5pp | -16.4%+86.1pp | -31.3%+182.2pp | N/A | -75.7%+118.6pp |
| Current Ratio | 5.86-4.4x | 0.89-4.0x | 1.98-1.5x | 5.81+4.0x | 10.22+9.9x | 4.94+4.7x | 3.43+3.2x | 1.82+1.3x |
| Debt-to-Equity | 0.21+0.1x | 64.54+64.3x | 0.91+0.5x | 0.20-1.0x | 0.11 | 0.25 | 0.41 | 1.21 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. CNSP | FY2025 | N/A | -$16K | N/A | $7.6M | — |
| Quoin Pharmaceuticals, Ltd. QNRX | FY2025 | N/A | -$15.8M | N/A | $9.0M | — |
| Oragenics Inc. OGEN | FY2025 | N/A | N/A | N/A | $2.1M | — |
| Jaguar Health, Inc. JAGX | FY2025 | $11.5M | -$54K | -0.5% | $2.5M | 33/100 |
| Theriva Biologics, Inc. TOVX | FY2025 | N/A | -$23.7M | N/A | $10.0M | — |
| Xenetic Biosciences, Inc. XBIO | FY2025 | $3.0M | -$2.7M | -90.1% | $5.0M | 66/100 |
Where CNS Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Is CNS Pharmaceuticals, Inc. profitable?
No, CNS Pharmaceuticals, Inc. (CNSP) reported a net income of -$16K in fiscal year 2025.
What is CNS Pharmaceuticals, Inc.'s EBITDA?
CNS Pharmaceuticals, Inc. (CNSP) had EBITDA of -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CNS Pharmaceuticals, Inc.'s return on equity (ROE)?
CNS Pharmaceuticals, Inc. (CNSP) has a return on equity of -0.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CNS Pharmaceuticals, Inc.'s free cash flow?
CNS Pharmaceuticals, Inc. (CNSP) recorded an outflow of $13.8M in free cash flow during fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CNS Pharmaceuticals, Inc.'s operating cash flow?
CNS Pharmaceuticals, Inc. (CNSP) recorded an outflow of $13.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CNS Pharmaceuticals, Inc.'s total assets?
CNS Pharmaceuticals, Inc. (CNSP) had $8.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are CNS Pharmaceuticals, Inc.'s capital expenditures?
CNS Pharmaceuticals, Inc. (CNSP) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does CNS Pharmaceuticals, Inc. spend on research and development?
CNS Pharmaceuticals, Inc. (CNSP) invested $9.8M in research and development during fiscal year 2025.
What is CNS Pharmaceuticals, Inc.'s current ratio?
CNS Pharmaceuticals, Inc. (CNSP) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.
What is CNS Pharmaceuticals, Inc.'s debt-to-equity ratio?
CNS Pharmaceuticals, Inc. (CNSP) had a debt-to-equity ratio of 0.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CNS Pharmaceuticals, Inc.'s return on assets (ROA)?
CNS Pharmaceuticals, Inc. (CNSP) had a return on assets of -0.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CNS Pharmaceuticals, Inc.'s P/E ratio?
CNS Pharmaceuticals, Inc. (CNSP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.6M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CNS Pharmaceuticals, Inc.'s price-to-sales ratio?
CNS Pharmaceuticals, Inc. (CNSP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.6M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does CNS Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, CNS Pharmaceuticals, Inc. (CNSP) held $7.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $13.8M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is CNS Pharmaceuticals, Inc.'s Piotroski F-Score?
CNS Pharmaceuticals, Inc. (CNSP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CNS Pharmaceuticals, Inc.'s earnings high quality?
CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $16K while operations used $13.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CNS Pharmaceuticals, Inc. cover its interest payments?
CNS Pharmaceuticals, Inc. (CNSP) reported an operating loss of $16.0M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.